This report was first published by Endpoints News. To see the original version, click here
InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday.
After nearly a year’s worth of treatment with the trial’s high dose of the drug, 57.1% of patients had a response on a disease activity scale called the SLE Responder Index-4, or SRI-4. That rate was better than the 34.4% of patients who responded in the placebo group, InnoCare said. The results were statistically significant.
您已阅读34%（593字），剩余66%（1126字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。